<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456974</url>
  </required_header>
  <id_info>
    <org_study_id>2012/172</org_study_id>
    <nct_id>NCT02456974</nct_id>
  </id_info>
  <brief_title>Antibiotic Dosing in Pediatric Intensive Care</brief_title>
  <acronym>ADIC</acronym>
  <official_title>Antibiotic Dosing in Pediatric Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Fabiola Children's University Hospital, Brussels</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics of antibiotics in critically ill neonates, infants and children
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">April 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>To investigate if first-dose blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens.</measure>
    <time_frame>2 years (expected)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate if steady-state blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens.</measure>
    <time_frame>2 years (expected)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare measured first-dose blood concentrations with predefined pharmacodynamic targets (Time above MIC)</measure>
    <time_frame>2 years (expected)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare measured steady-state blood concentrations with predefined pharmacodynamic targets (Time above MIC)</measure>
    <time_frame>2 years (expected)</time_frame>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Amoxicillin-clavulanate</condition>
  <condition>Piperacillin-tazobactam</condition>
  <condition>Vancomycin</condition>
  <condition>Teicoplanin</condition>
  <condition>Meropenem</condition>
  <condition>Ciprofloxacin</condition>
  <condition>Amikacin</condition>
  <arm_group>
    <arm_group_label>amoxicillin-clavulanate</arm_group_label>
    <description>Patients receiving amoxicillin-clavulanate as part of routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacilline-tazobactam</arm_group_label>
    <description>Patients receiving piperacilline-tazobactam as part of routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vancomycin</arm_group_label>
    <description>Patients receiving vancomycin as part of routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teicoplanin</arm_group_label>
    <description>Patients receiving teicoplanin as part of routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <description>Patients receiving meropenem as part of routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ciprofloxacin</arm_group_label>
    <description>Patients receiving ciprofloxacin as part of routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amikacin</arm_group_label>
    <description>Patients receiving amikcain as part of routine clinical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care</intervention_name>
    <arm_group_label>amoxicillin-clavulanate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.</intervention_name>
    <arm_group_label>piperacilline-tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling in patients receiving vancomycin as part of routine clinical care.</intervention_name>
    <arm_group_label>vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling in patients receiving teicoplanin as part of routine clinical care.</intervention_name>
    <arm_group_label>teicoplanin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling in patients receiving meropenem as part of routine clinical care.</intervention_name>
    <arm_group_label>meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.</intervention_name>
    <arm_group_label>ciprofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling in patients receiving amikacin as part of routine clinical care.</intervention_name>
    <arm_group_label>amikacin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and urine samples (only for ciprofloxacin)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        children admitted to a neonatal or pediatric intensive care unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients admitted to the pediatric intensive care unit

          -  patient age/weight : 1,8 kg-15 years

          -  patient receiving antibiotic treatment (piperacillin-tazobactam,
             amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin)
             via intermittent infusion regimen or continuous infusion according to institutional
             treatment guidelines

          -  intra-arterial or intravenous access other than the drug infusion line available for
             blood sampling (arterial line is preferred)

        Exclusion Criteria:

          -  no catheter in place for blood sampling

          -  absence of parental/patient consent

          -  known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones,
             aminoglycosides

          -  extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter De Cock</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter De Cock, PharmD</last_name>
    <phone>+32 9 332 29 69</phone>
    <email>pieter.decock@uzgent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital, Hospital Pharmacy</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter De Cock, PharmD</last_name>
      <phone>+3293322969</phone>
      <email>pieter.decock@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Pieter De Cock, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick de Jaeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Biarent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jozef De Dooy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

